A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio(®)) in cardiac surgery: the REVAKI‐1 study

AIMS: Acute kidney injury (AKI) is a common and severe complication of cardiac surgery. There is no effective prevention or treatment. Sildenafil citrate (Revatio(®), Pfizer Inc.), a phosphodiesterase type 5 inhibitor, prevents post cardiac surgery AKI in pre‐clinical studies, however its use is con...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Clin Pharmacol
Autors principals: Ring, Arne, Morris, Tom, Wozniak, Marcin, Sullo, Nikol, Dott, William, Verheyden, Veerle, Kumar, Tracy, Brunskill, Nigel, Vaja, Rakesh, Murphy, Gavin J.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2016
Matèries:
Clinical Trials
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346869/
https://ncbi.nlm.nih.gov/pubmed/27779776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13162
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars